Carlos A. Rodríguez

1.8k total citations
61 papers, 1.2k citations indexed

About

Carlos A. Rodríguez is a scholar working on Pharmacology, Infectious Diseases and Immunology. According to data from OpenAlex, Carlos A. Rodríguez has authored 61 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pharmacology, 11 papers in Infectious Diseases and 11 papers in Immunology. Recurrent topics in Carlos A. Rodríguez's work include Antibiotics Pharmacokinetics and Efficacy (19 papers), Economic Theory and Policy (9 papers) and Antimicrobial Resistance in Staphylococcus (8 papers). Carlos A. Rodríguez is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (19 papers), Economic Theory and Policy (9 papers) and Antimicrobial Resistance in Staphylococcus (8 papers). Carlos A. Rodríguez collaborates with scholars based in Colombia, United States and Puerto Rico. Carlos A. Rodríguez's co-authors include Andrés F. Zuluaga, Ómar Vesga, María Agudelo, Pablo E. Guidotti, Jacob A. Frenkel, Rodrigo Ochoa, Carlos Peláez, Juan Carlos Cataño, Javier González and Andrea Restrepo and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Journal of Allergy and Clinical Immunology.

In The Last Decade

Carlos A. Rodríguez

56 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carlos A. Rodríguez Colombia 16 377 353 243 151 149 61 1.2k
Laurence Roope United Kingdom 12 128 0.3× 36 0.1× 25 0.1× 57 0.4× 14 0.1× 48 835
Elias Bengtsson Sweden 21 138 0.4× 55 0.2× 70 0.3× 156 1.0× 270 1.8× 103 1.4k
Salma Akter Bangladesh 19 322 0.9× 30 0.1× 17 0.1× 432 2.9× 27 0.2× 77 1.5k
Sanchita Basu Das United States 14 40 0.1× 66 0.2× 117 0.5× 156 1.0× 14 0.1× 60 995
Xiaoxi Zhang China 10 92 0.2× 118 0.3× 9 0.0× 58 0.4× 36 0.2× 32 507
Geoffrey Edwards United Kingdom 34 54 0.1× 8 0.0× 346 1.4× 593 3.9× 18 0.1× 143 3.6k
Masao Nakamura Japan 16 96 0.3× 14 0.0× 23 0.1× 39 0.3× 240 1.6× 65 1.0k
Jennifer Rubin United States 17 108 0.3× 4 0.0× 32 0.1× 192 1.3× 126 0.8× 54 793
Gaurav Agrawal India 16 161 0.4× 97 0.3× 6 0.0× 140 0.9× 54 0.4× 43 1.0k
Peter Stephens United States 8 95 0.3× 3 0.0× 58 0.2× 47 0.3× 24 0.2× 20 595

Countries citing papers authored by Carlos A. Rodríguez

Since Specialization
Citations

This map shows the geographic impact of Carlos A. Rodríguez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos A. Rodríguez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos A. Rodríguez more than expected).

Fields of papers citing papers by Carlos A. Rodríguez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos A. Rodríguez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos A. Rodríguez. The network helps show where Carlos A. Rodríguez may publish in the future.

Co-authorship network of co-authors of Carlos A. Rodríguez

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos A. Rodríguez. A scholar is included among the top collaborators of Carlos A. Rodríguez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos A. Rodríguez. Carlos A. Rodríguez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
López, Lucelly, et al.. (2025). Effect of chemotherapy timing in triple-negative breast cancer: a real-world evidence study. Breast Cancer Research and Treatment. 212(2). 225–236.
2.
Rodríguez, Carlos A., et al.. (2020). A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone. PLoS ONE. 15(12). e0243365–e0243365. 7 indexed citations
3.
Agudelo, María, Carlos A. Rodríguez, Andrés F. Zuluaga, & Ómar Vesga. (2019). Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin. PLoS ONE. 14(2). e0211096–e0211096. 3 indexed citations
4.
Rodríguez, Carlos A., et al.. (2017). Conceptualización de la organización ambidiestra: desde la perspectiva de las capacidades dinámicas. Revista ESPACIOS. 38(34). 1 indexed citations
5.
6.
Rodríguez, Carlos A., María Agudelo, Andrés F. Zuluaga, & Ómar Vesga. (2016). In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products. International Journal of Antimicrobial Agents. 49(2). 189–197. 18 indexed citations
7.
Ochoa, Rodrigo, Carlos A. Rodríguez, & Andrés F. Zuluaga. (2016). Perspectives for the structure-based design of acetylcholinesterase reactivators. Journal of Molecular Graphics and Modelling. 68. 176–183. 18 indexed citations
8.
González, Javier, Carlos A. Rodríguez, María Agudelo, Andrés F. Zuluaga, & Ómar Vesga. (2016). Antifungal pharmacodynamics: Latin America's perspective. The Brazilian Journal of Infectious Diseases. 21(1). 79–87. 8 indexed citations
9.
Zuluaga, Andrés F., Carlos A. Rodríguez, María Agudelo, & Ómar Vesga. (2015). Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model. BMC Research Notes. 8(1). 546–546. 2 indexed citations
10.
Agudelo, María, Carlos A. Rodríguez, Andrés F. Zuluaga, & Ómar Vesga. (2014). Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam. International Journal of Antimicrobial Agents. 45(2). 161–167. 9 indexed citations
11.
Barros, Nicolas, Carlos A. Rodríguez, César Sánchez, et al.. (2013). CD4+ T cell subsets and Tax expression in HTLV-1 associated diseases. Pathogens and Global Health. 107(4). 202–206. 6 indexed citations
12.
Vesga, Ómar, et al.. (2010). Generic Vancomycin Products Fail In Vivo despite Being Pharmaceutical Equivalents of the Innovator. Antimicrobial Agents and Chemotherapy. 54(8). 3271–3279. 67 indexed citations
13.
Zuluaga, Andrés F., María Agudelo, Carlos A. Rodríguez, & Ómar Vesga. (2009). Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. PubMed. 9(1). 1–1. 86 indexed citations
14.
Rodríguez, Carlos A., et al.. (2008). METODOLOGIA PARA LA PROSPECCION DE NIQUEL UTILIZANDO TECNICAS DE SENSORES REMOTOS. SHILAP Revista de lepidopterología. 1 indexed citations
15.
Rodríguez, Carlos A.. (2007). Efectos aceleradores reales de la política monetaria estadounidense sobre una economía pequeña, abierta y totalmente dolarizada: el caso de Puerto Rico. Revista De Ciencias Sociales. 16(16). 30–47.
16.
17.
Restrepo, Andrea, et al.. (2005). Optimization of culture conditions to obtain maximal growth of penicillin-resistant Streptococcus pneumoniae. BMC Microbiology. 5(1). 34–34. 23 indexed citations
18.
Smith, David E., et al.. (1992). Effect of angiotensin II-induced changes in perfusion flow rate on chlorothiazide transport in the isolated perfused rat kidney. Journal of Pharmacokinetics and Biopharmaceutics. 20(2). 195–207. 4 indexed citations
19.
20.
Frenkel, Jacob A. & Carlos A. Rodríguez. (1975). Wealth Effects and the Dynamics of Inflation: Comment. Journal of money credit and banking. 7(2). 259–259. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laurence Roope Breakdown of academic impact, for papers by Elias Bengtsson Breakdown of academic impact, for papers by Salma Akter Breakdown of academic impact, for papers by Sanchita Basu Das Breakdown of academic impact, for papers by Xiaoxi Zhang Breakdown of academic impact, for papers by Geoffrey Edwards Breakdown of academic impact, for papers by Masao Nakamura Breakdown of academic impact, for papers by Jennifer Rubin Breakdown of academic impact, for papers by Gaurav Agrawal Breakdown of academic impact, for papers by Peter Stephens
Rankless by CCL
2026